CD133, Selectively Targeting the Root of Cancer
Cancer stem cells (CSC) are capable of promoting tumor initiation and self-renewal, two important hallmarks of carcinoma formation. This population comprises a small percentage of the tumor mass and is highly resistant to chemotherapy, causing the most difficult problem in the field of cancer resear...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-05-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6651/8/6/165 |
| _version_ | 1817996549722996736 |
|---|---|
| author | Jörg U. Schmohl Daniel A. Vallera |
| author_facet | Jörg U. Schmohl Daniel A. Vallera |
| author_sort | Jörg U. Schmohl |
| collection | DOAJ |
| description | Cancer stem cells (CSC) are capable of promoting tumor initiation and self-renewal, two important hallmarks of carcinoma formation. This population comprises a small percentage of the tumor mass and is highly resistant to chemotherapy, causing the most difficult problem in the field of cancer research, drug refractory relapse. Many CSC markers have been reported. One of the most promising and perhaps least ubiquitous is CD133, a membrane-bound pentaspan glycoprotein that is frequently expressed on CSC. There is evidence that directly targeting CD133 with biological drugs might be the most effective way to eliminate CSC. We have investigated two entirely unrelated, but highly effective approaches for selectively targeting CD133. The first involves using a special anti-CD133 single chain variable fragment (scFv) to deliver a catalytic toxin. The second utilizes this same scFv to deliver components of the immune system. In this review, we discuss the development and current status of these CD133 associated biological agents. Together, they show exceptional promise by specific and efficient CSC elimination. |
| first_indexed | 2024-04-14T02:23:52Z |
| format | Article |
| id | doaj.art-08ced24a9be044bcaac3ac28276b8c86 |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-04-14T02:23:52Z |
| publishDate | 2016-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-08ced24a9be044bcaac3ac28276b8c862022-12-22T02:17:56ZengMDPI AGToxins2072-66512016-05-018616510.3390/toxins8060165toxins8060165CD133, Selectively Targeting the Root of CancerJörg U. Schmohl0Daniel A. Vallera1University of Minnesota Masonic Cancer Center, Section of Molecular Cancer Therapeutics, Therapeutic Radiology-Radiation Oncology, University of Minnesota, Minneapolis, MN 55423, USAUniversity of Minnesota Masonic Cancer Center, Section of Molecular Cancer Therapeutics, Therapeutic Radiology-Radiation Oncology, University of Minnesota, Minneapolis, MN 55423, USACancer stem cells (CSC) are capable of promoting tumor initiation and self-renewal, two important hallmarks of carcinoma formation. This population comprises a small percentage of the tumor mass and is highly resistant to chemotherapy, causing the most difficult problem in the field of cancer research, drug refractory relapse. Many CSC markers have been reported. One of the most promising and perhaps least ubiquitous is CD133, a membrane-bound pentaspan glycoprotein that is frequently expressed on CSC. There is evidence that directly targeting CD133 with biological drugs might be the most effective way to eliminate CSC. We have investigated two entirely unrelated, but highly effective approaches for selectively targeting CD133. The first involves using a special anti-CD133 single chain variable fragment (scFv) to deliver a catalytic toxin. The second utilizes this same scFv to deliver components of the immune system. In this review, we discuss the development and current status of these CD133 associated biological agents. Together, they show exceptional promise by specific and efficient CSC elimination.http://www.mdpi.com/2072-6651/8/6/165cancer stem cellCD133relapseBIKEtargeted therapies |
| spellingShingle | Jörg U. Schmohl Daniel A. Vallera CD133, Selectively Targeting the Root of Cancer Toxins cancer stem cell CD133 relapse BIKE targeted therapies |
| title | CD133, Selectively Targeting the Root of Cancer |
| title_full | CD133, Selectively Targeting the Root of Cancer |
| title_fullStr | CD133, Selectively Targeting the Root of Cancer |
| title_full_unstemmed | CD133, Selectively Targeting the Root of Cancer |
| title_short | CD133, Selectively Targeting the Root of Cancer |
| title_sort | cd133 selectively targeting the root of cancer |
| topic | cancer stem cell CD133 relapse BIKE targeted therapies |
| url | http://www.mdpi.com/2072-6651/8/6/165 |
| work_keys_str_mv | AT jorguschmohl cd133selectivelytargetingtherootofcancer AT danielavallera cd133selectivelytargetingtherootofcancer |